GLP-3 RT10mg–60mg
$90Lyophilized GLP-3 RT supplied as a research reference standard.
Secure
Ordering
Same-Day
Dispatch
Third Party
Tested
Batch & Lot
Tracking
Free Ship
Over $200
Based in
the USA
Secure checkout · ACH bank transfer saves 5%
Supplied to qualified labs and institutional buyers. Institutional use & eligibility
Frequently researched together
GLP-3 RT
20mg
$150
KLOW
80mg
$195
CJC-1295 + Ipamorelin
10mg + 10mg
$190
Bundle total
$535
Researchers also viewed
View all
Sample Certificate of Analysis
Certificate of Analysis
GLP-3 RT
Lot Number
SAMPLE-LOT
Purity (HPLC)
≥99%
Nominal Fill
10mg
Example of the certificate format issued for this compound. Purity and specification figures are the published values for GLP-3 RT; the lot number and test date are shown only as placeholders. The certificate for the specific lot you receive is matched to the lot number printed on the vial. For laboratory research use only.
Characteristics
| Molar Mass | ~4605 g/mol |
|---|---|
| Amino Acid Sequence | 39-amino acid peptide; triple agonist acting on GIP, GLP-1, and glucagon receptors |
| Synonyms | GIP3, triple incretin research compound |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in aqueous buffers |
| Organoleptic Profile | White to off-white lyophilized powder; odorless |
| Storage Conditions | Store lyophilized at -20°C to 2-8°C; protect from light and moisture |
| Composition | Lyophilized peptide base |
How is GLP-3 RT used in research?
GIP3 is a novel triple hormone receptor agonist research compound that simultaneously activates GIP, GLP-1, and glucagon receptors. This tri-agonist approach represents the next evolution in incretin-based pharmacology research, building on dual agonism by incorporating glucagon receptor activity. In preclinical studies in rodent models, glucagon receptor agonism has been associated with increased energy-expenditure parameters, hepatic lipid-oxidation markers, and thermogenesis-related readouts, while the GIP and GLP-1 components modulate appetite-behavior and glycemic parameters in preclinical metabolic-parameter studies in rodent models.
The glucagon receptor component of this tri-agonist's activity profile is of particular scientific interest. Glucagon receptor agonism promotes hepatic glycogenolysis and gluconeogenesis, which under normal circumstances would elevate blood glucose. However, the concurrent GIP and GLP-1 receptor agonism appears to counterbalance this hyperglycemic potential in preclinical systems while allowing the metabolic signaling effects of glucagon, including energy-expenditure parameters, lipolysis markers, and amino-acid catabolism, to be studied in research models.
Preclinical studies in rodent models have demonstrated that rationally designed triple agonist peptides produce distinct preclinical metabolic-parameter profiles compared to dual or single agonists, including shifts in body-composition parameters, glucose-tolerance markers, and hepatic steatosis readouts in animal research models. These findings have generated substantial research interest in tri-agonism as a preclinical pharmacology research strategy.
Areas of Study
Triple Incretin Receptor Pharmacology
Tri-agonist engaging GIP, GLP-1, and glucagon receptors simultaneously in preclinical metabolic-parameter studies in rodent models, beyond dual agonism.
Energy Expenditure & Thermogenesis
Glucagon receptor agonism component studied for effects on energy-expenditure parameters and thermogenic markers in brown adipose tissue in rodent research models.
Hepatic Lipid Metabolism
Investigated for hepatic lipid-oxidation markers and steatosis-related readouts through combined incretin and glucagon receptor signaling in preclinical models.
Glycemic Regulation
Studied in preclinical models for glycemic-parameter shifts where the glucagon component's hyperglycemic potential is counterbalanced by GIP/GLP-1 activity.
Body-Composition Research
Preclinical rodent studies demonstrate body-composition parameter shifts compared to single or dual receptor agonists.
References
- [1]Finan B, Yang B, Ottaway N, et al. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine, 21(1), 27-36.
Disclaimer: Information provided for research reference only; not medical advice. Sold strictly for in-vitro research use.
Certificate of Analysis
Third-party verified
Every batch of GLP-3 RT is independently tested by an A2LA-accredited (ISO 17025:2017) laboratory using HPLC-UV/VIS for purity and identity, with a batch-specific lot number. Results are published publicly.
View COAsMore research compounds
View all
5-Amino-1MQ
from $55
AOD-9604
$110
Cagrilintide
from $100
GLP-1 SM
from $55
GLP-2 TZ
from $65
MOTS-c
from $55
SLU-PP
$110Frequently
Asked
Questions
Everything on purity, paperwork, shipping and the research-use-only terms. Still stuck? Read the full FAQ.
What does research use only mean?
Every compound we supply is a reference standard intended strictly for in-vitro laboratory research. It is not a drug or a supplement, and it is not for human or veterinary use, nor for diagnostic or therapeutic use.
How is purity verified?
Every lot is assayed by HPLC at an independent, accredited third-party laboratory. We publish the resulting Certificate of Analysis and link it to the lot number printed on the vial.
Where do I find the Certificate of Analysis?
Every lot has a public, batch-linked COA. Browse them all on the COA page, or open any product page and use the COA tab for that specific compound.
How quickly do orders ship?
Orders placed before 2PM EST ship the same business day. Shipments are cold-packed where required and fully tracked.
Do you ship internationally?
We currently ship within the United States. Requests from institutional buyers outside the US are handled case by case, so contact us before ordering.
Ready to Start
Your Research?
Browse the complete catalog of third-party verified, lyophilized research compounds. Orders before 2PM EST ship same day.